Maykin Ho - 28 May 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Director
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Maykin Ho
Issuer symbol
NMRA
Transactions as of
28 May 2025
Net transactions value
$0
Form type
4
Filing time
30 May 2025, 18:30:22 UTC
Previous filing
22 May 2025
Next filing
06 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ho Maykin Director C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN /s/ Michael Milligan, as Attorney-in-Fact for Maykin Ho 30 May 2025 0001646395

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -95,586 -100% 0 28 May 2025 Common Stock 95,586 $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -27,802 -100% 0 28 May 2025 Common Stock 27,802 $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -28,571 -100% 0 28 May 2025 Common Stock 28,571 $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Award +95,586 95,586 28 May 2025 Common Stock 95,586 $0.7200 Direct F1, F2, F3
transaction NMRA Stock Option (Right to Buy) Award +27,802 27,802 28 May 2025 Common Stock 27,802 $0.7200 Direct F1, F2, F3
transaction NMRA Stock Option (Right to Buy) Award +28,571 28,571 28 May 2025 Common Stock 28,571 $0.7200 Direct F1, F2, F3
transaction NMRA Stock Option (Right to Buy) Award $0 +80,000 $0.000000 80,000 28 May 2025 Common Stock 80,000 $0.7200 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested and exercisable.
F2 On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged.
F3 On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.
F4 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025.